Identification of neurofibromin mutants that exhibit allele specificity or increased Ras affinity resulting in suppression of activated ras alleles

Molecular and Cellular Biology

Volumn 16, Issue 5, 1996, Pages 2496-2503

  Morcos, Paul ^a   Thapar, Nitika ^a   Tusneem, Nadeem ^a   Stagey, Dennis ^b   Tamanoi, Fuyuhiko ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROFIBROMIN;

ALLELE; AMINO ACID SEQUENCE; ARTICLE; CELL INTERACTION; ENZYME ACTIVATION; GENE ACTIVATION; GENE REPRESSION; GROWTH INHIBITION; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; SCHWANN CELL;

EID: 0029880365     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.16.5.2496     Document Type: Article

References (42)

1. Baltester, R., D. Marchuck, M. Boguski, A. Sauline, R. Letcher, M. Wigler, and F. Collins. 1990. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63:851-859.
2. Basu, T. N., D. H. Gutmann, J. A. Fletcher, T. W. Glover, F. S. Collins, and J. Downward. 1992. Aberrant regulation of ras proteins in tumor cells from type 1 neurofibromatosis patients. Nature (London) 356:713-715.
3. Brtva, T. R., J. K. Drugan, S. Ghosh, R. S. Terrell, S. Campbell-Burk, R. M. Bell, and C. J. Der. 1995. Two distinct Raf domains mediate interaction with Ras. J. Biol. Chem 270:9809-9812.
4. Chien, C.-T., P. L. Bartel, R. Sternglanz, and S. Fields. 1991. The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest. Proc. Natl. Acad. Sci. USA 88:9578-9582
5. Créchet, J.-B., P. Poullet, J. Camonis, M. Jacquet, and A. Parmeggiani. 1990. Different kinetic properties of the two mutants, RAS2IIe152 and RAS2Val19, that suppress the CDC25 requirement in RAS/adenylate cyclase pathway in Saccharomyces cerevisiae. J. Biol. Chem. 265:1563-1568.
6. DeClue, J. E., A. G. Papageorge, J. Fletcher, S. R. Diehl, N. Ratner, W. C. Vass, and D. R. Lowy. 1992 Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69:265-273.
7. Durfee, T., K. Becherer, P.-L. Cheng, S.-H. Yeh, Y. Yang, A. E. Kilburn, W.-H. Lee, and S. J. Elledge. 1993. The retinoblastoma protein associates with the protein phrosphatase type 1 catalytic subunit Genes Dev. 7:555-569.
8. Fields, S., and O.-K. Song. 1989. A novel genetic system to detect protein-protein interactions. Nature (London) 340:245-246.
9. Fridman, M., A. Tikoo, M. Varga, A. Murphy, M. S. Nur-E-Kamal, and H. Maruta. 1994. The minimal fragments of c-Raf-1 and NF1 that can suppiess v-Ha-Ras-induced malignant phenotype. J. Biol. Chem. 269:30105-30108.
10. Gibbs, J. B., I. S. Sigal, M. Poe, and E. M. Scolnick. 1984. Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc. Natl. Acad. Sci. USA 81:5704-5708.
11. Gutmann, D. H., M. Boguski, D. Marchuk, M. Wigler, F. S. Collins, and R. Ballester. 1993. Analysis of the neurofibromatosis type 1 (NF1) GAP-related domain by site-directed mutagenesis Oncogene 8:761-769.
12. Hettich, L., and M. Marshall. 1994. Structural analysis of the Ras GTPase activating protein catalytic domain by semirandom mutagenesis: implications for a mechanism of interaction with Ras-GTP. Cancer Res. 54:5438-5444.
13. Ho, S. N., H. D. Hunt, R. M. Horton, J. K. Pullen, and L. R. Pease. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51-59.
14. Johnson, M. R., J. E. DeClue, S. Felzmann, W. C. Vass, G. Xu, R. Whits, and D. R. Lowy. 1994 Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function. Mol. Cell. Biol. 14:641-645.
15. Kim, H., T. Rosenbaum, M. A. Marchionni, N. Ratner, and J. E. DeClue, 1995 Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes. Oncogene 11:325-335.
16. Kim, M. R., and F. Tamanoi. Unpublished results.
17. Krengel, U., L. Schlichting, A. Scherer, R. Schumann, M. Frech, J. John, W. Kabsch, E. F. Pai, and A. Wittinghofer. 1990. Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. Cell 62:539-548.
18. Li, Y., G. Bollag, R. Clark, J. Stevens, L. Conroy, D. Fults, K. Ward, E. Friedman, W. Samowitz, M. Robertson, P. Bradley, F. McCormick, R. White, and R. Cawthon. 1992. Somatic mutations in the neuroribromatosis 1 gene in human tumors. Cell 69:275-281.
19. Lin, B., and F. Tamanoi. Unpublished results
20. Martin, G. A., D. Viscohil, G. Bollag, P. C. McCabe, W. J. Crosier, H. Haubruck, L. Conroy, R. Clark, R. O'Connel, R. M. Cawthon, M. A. Innis, and F. McCormick. 1990. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. 63:843-849.
21. McGlade, J., B. Brunkhorst, D. Anderson, G. Mbamalu, J. Settleman, S. Dedhar, M, rozakis-Adcock, L. B. Chen, and T. Pawson. 1993 The N-terminal region of GAP regulates cytoskeletal structure and cell adhesion. EMBO J 12:3073-3081.
22. Mitsuzawa, H., K. Esson, and F. Tamanoi. 1995 Mutant farnesyltransferase β subunit of Saccharomyces cerevisiae that can substitute for geranylgeranyl-transferase type I β subunit. Proc Natl Acad Sci. USA 92:1704-1708
23. Miura, K., Y. Inoue, H. Nakamori, S. Iwai, E. Ohtsuka, M. Ikehara, S. Noguchi, and S. Nishimura. 1986. Synthesis and expression of a synthetic gene for the activated human c-Ha-ras protein Jpn J. Cancer Res 77:45-51
24. Nakafuku, M., M. Nagamine, A. Ohtoshi, K. Tanaka, A. Toh-e, and Y. Kaziro. 1993 Suppression of oncogenic Ras by mutant neurofibromatosis type L genes with single amino acid substitutions. Proc. Natl. Acad. Sci. USA 90:6706-6710
25. Nur-E-Kamal, M. S., M. Varga, and H. Maruta. 1993 The GTPase-activating NF1 fragment of 91 amino acids reverses v-Ha-Ras-induced malignant phenotype. J. Biol. Chem. 268:22331-22337.
26. Val-19-activated phenotypes. Mol. Cell Biol. 14:815-821.
27. Poullet, P., and F. Tamanoi. 1995. Use of the yeast two-hybrid system to evaluate Ras interactions with NF1-GAP. Methods Enzymol. 255:488-497.
28. Prive, G. G., M. V. Milburn, L. Tong, A. M. de Vos, Z. Yamaizumi, S. Nishimura, and S. H. Kim. 1992. X-ray crystal structures of transforming p21 ras mutants suggest a transition-state stabilization mechanism for GTP hydrolysis. Proc. Natl Acad. Sci. USA 89:3649-3653.
29. Purandare, S. M., M. G. Lanyon, and J. M. Conner. 1994. Characterization of inherited and sporadic mutations in neurofibromatosis type-1. Hum. Mol. Genet. 3:1109-1115.
30. Riccardi, V. 1992 Neurofibromatosis: phenotype, natural history and pathogenesis, 2nd ed. Johns Hopkins University Press, Baltimore.
31. Rubinfeld, B., G. Wong, E. Bekesi, A. Wood, E. Heimer, F. McCormick, and P. Polakis. 1991. A synthetic peptide corresponding to a sequence in the GTPase activating protein inhibits p21ras stimulation and promotes guanine nucleotide exchange. Int. J. Peptide Protein Res. 38:47-53.
32. Skinner, R. H., S. Bradley, A. L. Brown, N. J. E. Johnson, S. Rhodes, D. K. Stammers, and P. N. Lowe. 1991. Use of the Glu-Glu-Phe C-terminal epitope for rapid purification of the catalytic domain of normal and mutant ras GTPase-activating proteins. J Biol Chem 266:14163-14166.
33. Smith, D. B., and K. S. Johnson. 1988. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 67:331-340.
34. ras effector function and GTPase-activating protein interaction Mol. Cell. Biol. 13:7311-7320.
35. Tanaka, K., D. R. Wood, B. K. Lin, M. Khalil, F. Tamanoi, and J. F. Cannon. 1992. A dominant activating mutation in the effector region of RAS abolishes IRA2 sensitivity. Mol. Cell. Biol. 12:631-637.
36. Toda, T., I. Lino, T. Ishikawa, S. Powers, T. Kataoka, D. Broek, S. Cameron, J. Broach, K. Matsumoto, and M. Wigler. 1985. In yeast, RAS proteins are controlling elements of adenylate cyclase. Cell 40:27-36.
37. Upadhaya, M. Personal communication.
38. Vogel, K. S., C. I. Brannan, N. A. Jenkins, N. G. Copeland, and L. F. Parada. 1995. Loss of neurofibromin results in neurotropin-independent survival of embryonic sensory and sympathetic neurons. Cell 82:733-742.
39. Wang, Y., M. Boguski, M. Riggs, L. Rodgers, and M. Wigler. 1991. sar1, a gene from Schizosaccharomyces pombe encoding a protein that regulates ras1. Cell. Regul 2:453-465
40. Wilson, B. A., M. Khalil, F. Tamanoi, and J. C. Cannon. 1993. New activated RAS2 mutations identified in Saccharomyces cerevisiae Oncogene 8:3441-3445.
41. Wood, D. R., P. Poullet, B, A. Wilson, M. Khalil, K. Tanaka, J. F. Cannon, and F. Tamanoi. 1994 Biochemical characterization of yeast RAS2 mutants reveals a new region of ras protein involved in the interaction with GTPase-activating proteins. J. Biol. Chem. 269:5322-5327.
42. Xu, G., B. K. Lin, K. Tanaka, D. Dunn, D. R. Wood, R. Gesteland, R. White, R. Weiss, and F. Tamanoi. 1990. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S cerevisiae Cell 63:835-841.